F2G
PrivateLast Round
Series H
Sep 12, 2024
Total Funding Raised
$103.45M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
F2G operates in Healthcare & Life Sciences and is based in Macclesfield. Its latest recorded funding round was a VC Round in August 2022.
F2G is a biotechnology company that develops novel therapies for the treatment of life-threatening invasive fungal infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
F2G Comparables
Compare F2G with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biosergen AB | 84% | |
| Basilea Pharmaceutica | 80% | |
| Scynexis Inc | 78% |
For institutional investors. Book with your work email.
F2G Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series H | Sep 12, 2024 | ||||
| VC Round | Aug 4, 2022 | ||||
| Series F | Aug 12, 2020 | ||||
| VC Round | Jan 7, 2019 | ||||
| Debt | Nov 22, 2018 | ||||
VC Round | Jun 20, 2016 |
For institutional investors. Book with your work email.
F2G Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Heartcore Capital | VC Round |
| Owl Rock Capital Group | Series H |
| AMR Action Fund | Series H |
| Brace Pharma Capital | Series H, VC Round, Series F |
| Forbion | Series H, VC Round |
| BankInvest | Series A |
| Intermediate Capital Group | Series H |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2026
Open roles increased to 24, 2.6x the trailing average.
- Sep 7, 2026
Open roles increased to 17, 2.3x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 21, 2026
F2G, Ltd. announces at IDWeek on Oct 21st '26 that oral antifungal olorofim succeeds in a late-stage clinical trial, supporting FDA consideration later in 2026.
- attends_eventSep 1, 2026
F2G, Ltd. attends the MSGERC 2026 Biennial Meeting in Colorado from Sep 9th–11th '26, with abstracts accepted for presentation, including one presented by its Vice President of Clinical R&D.
For institutional investors. Book with your work email.
F2G Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about F2G's valuation, stock price, and market status.
Is F2G a public or private company?
F2G is a private company.
What is the current stock price of F2G?
F2G is a private company, so its shares have no public market price. Caplight tracks F2G's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is F2G worth (valuation)?
Valuation information for F2G is not publicly available.
Can I buy F2G stock?
F2G shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was F2G's last funding round?
F2G's most recent funding round was Series H on September 12, 2024.
Who are the main investors in F2G?
Key investors in F2G include AMR Action Fund, Forbion, BankInvest, Intermediate Capital Group, Advent Life Sciences.
Will F2G IPO soon?
No public IPO plans have been announced for F2G.
How can I track F2G secondary market activity?
Caplight tracks bids, offers, and trades in F2G's shares on secondary markets.